On this page
What each program costs in Wisconsin
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the Wisconsin Group Health Insurance Program (ETF) cover GLP-1s for weight loss?
Wisconsin's state Group Health Insurance Program has excluded weight-loss drugs. In March 2026 the Group Insurance Board approved covering GLP-1 anti-obesity medications for non-Medicare members from January 1, 2027, with a $200 copay.
Wisconsin Department of Employee Trust Funds
ETF's August 2024 Board presentation says weight-loss drugs have always been excluded from the program.
“Weight-loss drugs have always been excluded from the Group Health Insurance Program.”
https://etf.wi.gov/boards/groupinsurance/2024/08/14/gib4ppt · read Oct 29, 2026
Wisconsin Department of Employee Trust Funds
ETF's March 16, 2026 news item says the Board approved anti-obesity medication coverage for non-Medicare members starting January 1, 2027.
“In addition, the Board approved coverage of AOMs at a separate cost-sharing level for non-Medicare members, effective January 1, 2027.”
https://etf.wi.gov/news/gib-approves-cost-sharing-glp-1s-weight-loss-2027 · read Oct 29, 2026
Wisconsin Department of Employee Trust Funds
Members will pay a $200 copay for these drugs.
“Members will have a $200 copay for these weight-loss drugs.”
https://etf.wi.gov/news/gib-approves-cost-sharing-glp-1s-weight-loss-2027 · read Oct 29, 2026
Does Wisconsin Medicaid (BadgerCare Plus) cover GLP-1s for weight loss?
Zepbound yes, Wegovy no
Wisconsin Medicaid covers Zepbound for weight management with prior authorization and BMI rules, but its Wegovy weight criteria apply only to ages 12 to 17, and adult Wegovy approvals are limited to heart risk and a liver condition. Read from state documents Nov 6, 2026.
What Wisconsin Medicaid (BadgerCare Plus)'s documents say about each drug for weight loss. Read Nov 6, 2026. Wisconsin Department of Health Services, Division of Medicaid Services.
WegovyNo
Adults: approved only for heart risk with established cardiovascular disease or for MASH, not weight loss. A weight path exists only for ages 12 to 17, injection only, BMI at or above the 95th percentile, with prior authorization.
“PA requests for Wegovy injection will only be approved for use in the identified clinical conditions:”
Wisconsin DHS, ForwardHealth (Internet Archive copy of 22 Oct 2026; the state host refused our reader) · Effective Jul 1, 2026 · read Nov 6, 2026
“To reduce excess body weight and maintain weight reduction long term in pediatric patients aged 12 years and older with obesity”
Wisconsin DHS, ForwardHealth (Internet Archive copy of 22 Oct 2026; the state host refused our reader) · Effective Jul 1, 2026 · read Nov 6, 2026
“The member has a BMI greater than or equal to the 95th percentile standardized by age and gender.”
Wisconsin DHS, ForwardHealth (Internet Archive copy of 22 Oct 2026; the state host refused our reader) · Effective Jul 1, 2026 · read Nov 6, 2026
ZepboundYes
Prior authorization required. BMI 30 or higher, or BMI 27 to under 30 with two or more listed risk factors, plus agreement to a reduced-calorie diet and more physical activity. One weight management agent at a time.
“Foundayo and Zepbound will become preferred drugs in the weight management agents drug class.”
Wisconsin DHS, ForwardHealth (Internet Archive copy of 22 Oct 2026; the state host refused our reader) · Effective Jul 1, 2026 · read Nov 6, 2026
“The member has a body mass index (BMI) greater than or equal to 30.”
Wisconsin DHS, ForwardHealth (Internet Archive copy of 22 Oct 2026; the state host refused our reader) · Effective Jul 1, 2026 · read Nov 6, 2026
“The member has a BMI greater than or equal to 30.”
Wisconsin DHS, ForwardHealth · Effective Jul 1, 2026 · read Nov 6, 2026
OzempicNot confirmed
No state document read names Ozempic's weight-loss status. Update 2026-15 does not mention Ozempic. It says weight management agents outside the new class are noncovered, but does not say that reaches Ozempic. The live ForwardHealth portal refused connections.
MounjaroUnclear
Update 2026-15 makes Mounjaro preferred in the hypoglycemics GLP-1 class and says preferred agents there do not require PA, with no weight-loss statement for Mounjaro. The same Update says weight management agents outside the new class are noncovered. Together these do not settle weight-loss use.
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Wisconsin Department of Health Services, Division of Medicaid Services documents. KFF's January 2026 map listed this program as covered; the documents we read agree.
- Jul 1, 2026 · Policy changeAdded a weight management drug class with Zepbound and Foundayo preferred, prior authorization required.
“Effective July 1, 2026, ForwardHealth will add weight management agents as a new drug class to the PDL.”
Wisconsin DHS, ForwardHealth (Internet Archive copy of 22 Oct 2026) · Effective Jul 1, 2026 · read Nov 6, 2026
Weight loss
Zepbound only, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
177,176 prescriptions
Ozempic and Mounjaro, 2025
29,477 prescriptions
Neighbours covering weight loss
2 of 4
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Wisconsin Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Wisconsin Medicaid as "covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Wisconsin Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Wisconsin Medicaid pay for?
302,633 GLP-1 prescriptions in 2025, 8th of the 50 states and DC, with $320.7 million reimbursed before rebates. Counting the share other payers covered, $327.8 million.
Prescriptions, 2025
302,633
8th of 51
Medicaid paid
$320.7M
8th of 51, before rebates
Per prescription
$1,060
$1,051 nationally
Weight-loss brands
59%
3rd highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Wisconsin is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 59% of Wisconsin Medicaid's GLP-1 prescriptions in 2025 (177,176). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Zepbound was Wisconsin Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Zepboundapproved for weight management | 110,688 | 37% | $116.7 million | $1,054 |
| Trulicity | 91,122 | 30% | $86.2 million | $946 |
| Wegovyapproved for weight management | 65,114 | 22% | $84.8 million | $1,303 |
| Ozempic | 22,045 | 7.3% | $21.1 million | $956 |
| Mounjaro | 7,432 | 2.5% | $7.7 million | $1,037 |
| Liraglutide (generic) | 3,267 | 1.1% | $1.6 million | $490 |
| Saxendaapproved for weight management | 1,374 | 0.5% | $1.5 million | $1,114 |
| Victoza | 1,179 | 0.4% | $727,587 | $617 |
| Rybelsus | 309 | 0.1% | $297,033 | $961 |
| Byetta | 76 | 0.0% | $63,304 | $833 |
| Exenatide (generic) | 27 | 0.0% | $21,383 | $792 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
Which FDA-registered outsourcing facilities are in Wisconsin?
FDA's register of 503B outsourcing facilities, updated Nov 17, 2026, lists 1 in Wisconsin. The register does not say which, if any, supplies a program on this page.
- Bennett Pharmaceuticals of America LLC, Hudson. Registered since Apr 19, 2022; not yet inspected by FDA.
On Medicare in Wisconsin?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Wisconsin and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
2 of the 4 states next to Wisconsin cover GLP-1s for weight loss through Medicaid: Michigan and Minnesota. None has a lower cash floor than Wisconsin's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Wisconsin | Zepbound only | 19 | $39/mo |
| Illinois | Not covered | 19 | $39/moWellmedr |
| Iowa | Not covered | 19 | $39/moWellmedr |
| Michigan | Covered | 19 | $39/moWellmedr |
| Minnesota | Covered | 19 | $39/moWellmedr |






















